Want to see GLUE full AI Analyst Report?
GLUE Stock Chart & Stats
$19.78
-$0.20(-2.99%)
At close: 4:00 PM EST
$19.78
-$0.20(-2.99%)
Day’s Range― - ―
52-Week Range$4.12 - $25.77
Previous CloseN/A
Volume283.19K
Average Volume (3M)949.96K
Market Cap
$1.88B
Enterprise Value$1.08B
Total Cash (Recent Filing)$666.22M
Total Debt (Recent Filing)$39.06M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding84,479,416
10 Day Avg. Volume1,240,953
30 Day Avg. Volume949,961
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)5.59
Price to Sales (P/S)10.53
P/FCF Ratio-47.37
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue25.10
Enterprise Value/Gross Profit26.34
Enterprise Value/Ebitda-8.73
Forecast
1Y Price Target
$33.50Price Target Upside69.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$46.05M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and expanding assets give the company durable financial flexibility to fund clinical programs, absorb R&D variability, and negotiate partnerships without immediate reliance on dilutive equity. This reduces refinancing risk and supports multi-quarter development timelines.
High Gross Margins On RevenueWhen revenue is realized, it shows very high gross margins tied to collaboration/licensing economics. Those structurally high margins mean incremental partner revenue would flow strongly to operating leverage, improving long-term profitability if revenue becomes steadier.
Ability To Generate Partnership RevenueThe sharp revenue pickup reflects successful collaboration/licensing activity and validates the QuEEN platform commercially. Structural partnership revenue sources (upfronts, R&D funding, milestones) can fund pipeline advancement and de-risk programs over multiple quarters.
Bears Say
Large, Persistent Net LossesSustained, large net losses erode equity and indicate the company is not yet covering operating costs from revenue. Over time this necessitates external financing or partner reliance, can dilute shareholders, and constrains long-term investment choices if losses continue.
Cash Flow Volatility And Recent BurnInconsistent cash generation—positive in 2024 but negative in the TTM—creates funding uncertainty for clinical programs. This volatility drives a structural need for milestone-based partner funding or new financing, increasing execution risk and potential program delays.
Revenue Volatility And Recent DeclineRevenue swings reflect milestone timing and partner dependency, producing irregular top-line performance. Such step-function revenues hinder predictable operating leverage, complicate budgeting for multi-stage trials, and increase the chance of periodic cash shortfalls.
Monte Rosa Therapeutics News
GLUE FAQ
What was Monte Rosa Therapeutics, Inc.’s price range in the past 12 months?
Monte Rosa Therapeutics, Inc. lowest stock price was $4.12 and its highest was $25.77 in the past 12 months.
What is Monte Rosa Therapeutics, Inc.’s market cap?
Monte Rosa Therapeutics, Inc.’s market cap is $1.88B.
When is Monte Rosa Therapeutics, Inc.’s upcoming earnings report date?
Monte Rosa Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 38 days.
How were Monte Rosa Therapeutics, Inc.’s earnings last quarter?
Monte Rosa Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.062.
Is Monte Rosa Therapeutics, Inc. overvalued?
According to Wall Street analysts Monte Rosa Therapeutics, Inc.’s price is currently Undervalued.
Does Monte Rosa Therapeutics, Inc. pay dividends?
Monte Rosa Therapeutics, Inc. does not currently pay dividends.
What is Monte Rosa Therapeutics, Inc.’s EPS estimate?
Monte Rosa Therapeutics, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Monte Rosa Therapeutics, Inc. have?
Monte Rosa Therapeutics, Inc. has 84,479,416 shares outstanding.
What happened to Monte Rosa Therapeutics, Inc.’s price movement after its last earnings report?
Monte Rosa Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went down -2.845%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GLUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monte Rosa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.50 (69.36% Upside)
$33.50 (69.36% Upside)
Blogger Sentiment
Bullish
GLUE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 666.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $424.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
378.32%
12-Months-Change
Fundamentals
Return on Equity
-40.99%
Trailing 12-Months
Asset Growth
87.29%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
GLUE Stock 12 Month Forecast
Average Price Target
$33.50
▲(69.36% Upside)
Technical Analysis
CytomX Therapeutics
―
Fulcrum Therapeutics
―
Monopar Therapeutics Inc
―
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.16% Insiders
15.12% Mutual Funds
57.34% Other Institutional Investors
2.25% Public Companies and
Individual Investors